Cellebrite DI (NASDAQ:CLBT) Sees Strong Trading Volume – Here’s Why

Cellebrite DI Ltd. (NASDAQ:CLBT) saw unusually-high trading volume on Monday . Approximately 3,496,200 shares were traded during mid-day trading, an increase of 100% from the previous session’s volume of 1,752,250 shares.The stock last traded at $13.1280 and had previously closed at $12.95.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CLBT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Needham & Company LLC lowered their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Finally, Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Stock Performance

The firm has a market cap of $3.29 billion, a price-to-earnings ratio of 42.16, a price-to-earnings-growth ratio of 1.99 and a beta of 1.30. The firm’s 50 day moving average is $14.52 and its 200-day moving average is $16.74.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. During the same period last year, the company earned $0.10 earnings per share. The business’s revenue was up 28.8% compared to the same quarter last year. As a group, research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Institutional Investors Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLBT. Voss Capital LP grew its holdings in Cellebrite DI by 18.9% during the fourth quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after purchasing an additional 1,277,300 shares during the last quarter. Pertento Partners LLP raised its position in shares of Cellebrite DI by 28.2% in the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares during the period. Invesco Ltd. lifted its stake in shares of Cellebrite DI by 0.8% in the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock worth $101,026,000 after buying an additional 43,041 shares during the last quarter. Granahan Investment Management LLC boosted its holdings in shares of Cellebrite DI by 16.3% during the 4th quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after buying an additional 427,719 shares during the period. Finally, Cooper Creek Partners Management LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter worth $55,999,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.